Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Afinitor, Afinitor Disperz, Certican, Zortress
Everolimus is an immunosuppressant drug used to prevent organ rejection after transplantation and to treat certain types of cancers. It belongs to a class of medications called mTOR inhibitors, which work by blocking a protein called mTOR that plays a crucial role in cell growth and proliferation. By inhibiting mTOR, everolimus slows down the growth and division of cells, including immune cells that attack transplanted organs and cancer cells.
Everolimus is used to prevent organ rejection after kidney, liver, and heart transplants, and to treat certain cancers such as advanced renal cell carcinoma, subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC), and advanced pancreatic neuroendocrine tumors.
Increased risk of serious infections, including fungal, bacterial, and viral infections. May increase the risk of developing certain types of cancers, including lymphoma and skin cancer. May cause impaired wound healing.
Outcome:
Increased everolimus levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Increased everolimus levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Decreased everolimus absorption
Mechanism:
Reduced bioavailability
Most likely new formulation: Extended-release injectable formulation (Year: 2026, 80% confidence)
Based on usage trends and clinical trial outcomes, there is a 70% likelihood of everolimus expanding its indications for use in other cancer types within the next 5 years.
Immunosuppressant, Antineoplastic
Macrolide derivative